106 related articles for article (PubMed ID: 23016776)
1. The immunohistochemical assessment of HPV related adenocarcinoma: pathologic and clinical prognostic significance.
Balan R; Căruntu ID; Amălinei C
Curr Pharm Des; 2013; 19(8):1430-8. PubMed ID: 23016776
[TBL] [Abstract][Full Text] [Related]
2. Endocervical adenocarcinomas with prominent endometrial or endomyometrial involvement simulating primary endometrial carcinomas: utility of HPV DNA detection and immunohistochemical expression of p16 and hormone receptors to confirm the cervical origin of the corpus tumor.
Yemelyanova A; Vang R; Seidman JD; Gravitt PE; Ronnett BM
Am J Surg Pathol; 2009 Jun; 33(6):914-24. PubMed ID: 19295407
[TBL] [Abstract][Full Text] [Related]
3. Unusual endocervical adenocarcinomas: an immunohistochemical analysis with molecular detection of human papillomavirus.
Park KJ; Kiyokawa T; Soslow RA; Lamb CA; Oliva E; Zivanovic O; Juretzka MM; Pirog EC
Am J Surg Pathol; 2011 May; 35(5):633-46. PubMed ID: 21490443
[TBL] [Abstract][Full Text] [Related]
4. Immunohistochemistry and HPV in situ hybridization in pathologic distinction between endocervical and endometrial adenocarcinoma: a comparative tissue microarray study of 76 tumors.
Jones MW; Onisko A; Dabbs DJ; Elishaev E; Chiosea S; Bhargava R
Int J Gynecol Cancer; 2013 Feb; 23(2):380-4. PubMed ID: 23318908
[TBL] [Abstract][Full Text] [Related]
5. Immunohistochemical p16 overexpression and Rb loss correlate with high-risk human papillomavirus infection in endocervical adenocarcinomas.
Yasutake N; Yamamoto H; Kuga R; Jiromaru R; Hongo T; Katayama Y; Sonoda K; Yahata H; Kato K; Oda Y
Histopathology; 2024 Jun; 84(7):1178-1191. PubMed ID: 38445509
[TBL] [Abstract][Full Text] [Related]
6. p16 expression in primary ovarian mucinous and endometrioid tumors and metastatic adenocarcinomas in the ovary: utility for identification of metastatic HPV-related endocervical adenocarcinomas.
Vang R; Gown AM; Farinola M; Barry TS; Wheeler DT; Yemelyanova A; Seidman JD; Judson K; Ronnett BM
Am J Surg Pathol; 2007 May; 31(5):653-63. PubMed ID: 17460447
[TBL] [Abstract][Full Text] [Related]
7. Intestinal-type endocervical adenocarcinoma in situ: an immunophenotypically distinct subset of AIS affecting older women.
Howitt BE; Herfs M; Brister K; Oliva E; Longtine J; Hecht JL; Nucci MR
Am J Surg Pathol; 2013 May; 37(5):625-33. PubMed ID: 23552379
[TBL] [Abstract][Full Text] [Related]
8. Intestinal-type cervical adenocarcinoma in situ and adenocarcinoma exhibit a partial enteric immunophenotype with consistent expression of CDX2.
McCluggage WG; Shah R; Connolly LE; McBride HA
Int J Gynecol Pathol; 2008 Jan; 27(1):92-100. PubMed ID: 18156982
[TBL] [Abstract][Full Text] [Related]
9. Endocervical Adenocarcinoma With Morphologic Features of Both Usual and Gastric Types: Clinicopathologic and Immunohistochemical Analyses and High-risk HPV Detection by In Situ Hybridization.
Wada T; Ohishi Y; Kaku T; Aman M; Imamura H; Yasutake N; Sonoda K; Kato K; Oda Y
Am J Surg Pathol; 2017 May; 41(5):696-705. PubMed ID: 28296678
[TBL] [Abstract][Full Text] [Related]
10. p16INK4A overexpression and HPV infection in uterine cervix adenocarcinoma.
Missaoui N; Hmissa S; Frappart L; Trabelsi A; Ben Abdelkader A; Traore C; Mokni M; Yaacoubi MT; Korbi S
Virchows Arch; 2006 May; 448(5):597-603. PubMed ID: 16496173
[TBL] [Abstract][Full Text] [Related]
11. Human papillomavirus 16/18 expression of endocervical glandular lesions: relationship with p53 and MIB-1 Expressions.
Yoon HK; Kim YJ; Kang MS
J Korean Med Sci; 2001 Apr; 16(2):169-74. PubMed ID: 11306742
[TBL] [Abstract][Full Text] [Related]
12. Dysregulation of CDK inhibitors and p53 in HPV-negative endocervical adenocarcinoma.
Omori M; Hashi A; Kondo T; Katoh R; Hirata S
Int J Gynecol Pathol; 2015 Mar; 34(2):196-203. PubMed ID: 25675191
[TBL] [Abstract][Full Text] [Related]
13. Endocervical adenocarcinomas with ovarian metastases: analysis of 29 cases with emphasis on minimally invasive cervical tumors and the ability of the metastases to simulate primary ovarian neoplasms.
Ronnett BM; Yemelyanova AV; Vang R; Gilks CB; Miller D; Gravitt PE; Kurman RJ
Am J Surg Pathol; 2008 Dec; 32(12):1835-53. PubMed ID: 18813124
[TBL] [Abstract][Full Text] [Related]
14. P16 as a molecular biomarker of cervical adenocarcinoma.
Schorge JO; Lea JS; Elias KJ; Rajanbabu R; Coleman RL; Miller DS; Ashfaq R
Am J Obstet Gynecol; 2004 Mar; 190(3):668-73. PubMed ID: 15041997
[TBL] [Abstract][Full Text] [Related]
15. New developments in endocervical glandular lesions.
McCluggage WG
Histopathology; 2013 Jan; 62(1):138-60. PubMed ID: 23134447
[TBL] [Abstract][Full Text] [Related]
16. The developing spectrum of gastric-type cervical glandular lesions.
Talia KL; McCluggage WG
Pathology; 2018 Feb; 50(2):122-133. PubMed ID: 29233547
[TBL] [Abstract][Full Text] [Related]
17. Cyclin D1 immunoreactivity in normal endocervix and diagnostic value in reactive and neoplastic endocervical lesions.
Little L; Stewart CJ
Mod Pathol; 2010 Apr; 23(4):611-8. PubMed ID: 20062011
[TBL] [Abstract][Full Text] [Related]
18. A retrospective study on incidence, diagnosis, and clinical outcome of gastric-type endocervical adenocarcinoma in a single institution.
Radomska A; Lee D; Neufeld H; Korte N; Torlakovic E; Agrawal A; Chibbar R
Diagn Pathol; 2021 Jul; 16(1):68. PubMed ID: 34332600
[TBL] [Abstract][Full Text] [Related]
19. Utility of p16 expression for distinction of uterine serous carcinomas from endometrial endometrioid and endocervical adenocarcinomas: immunohistochemical analysis of 201 cases.
Yemelyanova A; Ji H; Shih IeM; Wang TL; Wu LS; Ronnett BM
Am J Surg Pathol; 2009 Oct; 33(10):1504-14. PubMed ID: 19623034
[TBL] [Abstract][Full Text] [Related]
20. Immunophenotype analysis using CLDN18, CDH17, and PAX8 for the subcategorization of endocervical adenocarcinomas in situ: gastric-type, intestinal-type, gastrointestinal-type, and Müllerian-type.
Asaka S; Nakajima T; Kugo K; Kashiwagi R; Yazaki N; Miyamoto T; Uehara T; Ota H
Virchows Arch; 2020 Apr; 476(4):499-510. PubMed ID: 31932920
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
